Sujith Ramachandran and Xiaoning Huang highlight the growing financial impact and clinical benefits of GLP-1 medications as usage surges across the United States.
Sujith Ramachandran, an associate professor of pharmacy administration, and Xiaoning Huang, an assistant professor of medicine, have identified significant trends in the rising popularity and cost of GLP-1 medications. While these drugs provide substantial health value, the administration of such treatments faces challenges regarding long-term affordability and budget impact. Research indicates that while total payments per user have climbed sharply, out-of-pocket costs for patients have generally decreased due to expanded insurance coverage. However, Sujith Ramachandran notes that the massive patient population eligible for these drugs can create a significant budget impact for society. Furthermore, Xiaoning Huang warns that higher drug spending often leads to increased insurance premiums and higher deductibles for all payers. Experts also caution that medication alone is not a complete solution; patients require lifestyle support, such as gym memberships and dietetic guidance, to maintain results. While compounded alternatives offer lower prices, researchers warn that these products may lack the rigorous oversight of the FDA, potentially leading to safety risks if not monitored by a physician.